%0 Journal Article %A Fabiola Atzeni %A Luisa Costa %A Francesco Caso %A Raffaele Scarpa %A Piercarlo Sarzi-Puttini %T Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis %D 2015 %R 10.3899/jrheum.150643 %J The Journal of Rheumatology %P 79-81 %V 93 %X Psoriatic arthritis (PsA) is a systemic inflammatory disease characterized by possible peripheral and axial joint involvement, enthesitis, dactylitis, and skin and nail disease. It affects up to one-third of psoriatic patients, and may be associated with comorbidities such as cardiovascular and metabolic diseases. The usually prescribed initial treatment of moderate-severe PsA is methotrexate, which may be accompanied or replaced by a tumor necrosis factor (TNF) inhibitor such as etanercept, infliximab, or adalimumab. However, some patients may become unresponsive (or have contraindications) to available anti-TNF agents and require alternative treatment. The aim of this review is to describe the potential role of some new immunomodulatory agents. %U https://www.jrheum.org/content/jrheumsupp/93/79.full.pdf